Introduction
Monoamine transporter proteins play a fundamental role in limiting the extent of nonsynaptic volume transmission in the central nervous system (Rice and Cragg, 2008; Vizi et al., 2010) . Amphetamine-type stimulants target these transporters by acting as substrates and triggering the efflux of monoamine transmitters, especially dopamine (DA) and norepinephrine (NE) (Rothman and Baumann, 2003; Fleckenstein et al., 2007) . Drug-induced increases in extracellular monoamines produce a spectrum of effects in animals that includes forward locomotion, stereotypy and reward-relevant behaviors like drug self-administration (for review see (Rothman and Baumann, 2006; Newman and Rothman, 2007) . Substantial evidence indicates that DA, rather than NE, is the most critical mediator of reward-relevant properties of stimulant drugs (Wise, 2008) . In humans, certain stimulant drugs are commonly abused (e.g., cocaine and methamphetamine) whereas others are prescribed as efficacious treatments for psychiatric conditions like attention deficit hyperactivity disorder (e.g., methylphendiate and amphetamine). It is noteworthy that stimulant medications are among the most promising candidates for treating cocaine and methamphetamine dependence (Grabowski et al., 2004; Mooney et al., 2009) .
Given the widespread therapeutic use of stimulants, it seems prudent to evaluate strategies for decreasing the abuse liability these agents. Studies dating back to the 1980s (Lyness, 1983) demonstrate that increasing serotonergic tone can decrease stimulant selfadministration. Additionally, drug treatments that simultaneously elevate extracellular DA and 5-HT are not as readily self-administered as drug treatments that elevate DA alone (Roberts et al., 1999; Rothman et al., 2005; Wee and Woolverton, 2006; Howell et al., 2007) . In a representative study, Wee and Woolverton (Wee and Woolverton, 2006) To further explore the interactions between DA and 5-HT release in the brain, we have characterized the pharmacology of amphetamine analogs derived from an extensive library of phenylethylamine compounds (i.e., PAL compounds). In particular, we have focused on four PAL analogs which display similar in vitro potency as DA releasers but differ in potency as 5-HT releasers (Wee et al., 2005 ) (see Figure 1 for structures). The selectivity for DA release vs. 5-HT release for these drugs ranges from 80-fold DA-selective for m-fluoroamphetamine (PAL-353) to non-selective for p-methylamphetamine (PAL-313) (see Table 1 ). Various behavioral effects of these analogs in rats and non-human primates have been reported (Wee et al., 2005; Negus et al., 2007; Kimmel et al., 2009; Wellman et al., 2009), and Kimmel et al. (2009) used in vivo microdialysis in squirrel monkey n. accumbens to demonstrate that PAL-313 evokes significantly less DA release than PAL-353. Interestingly, PAL-313 supports less selfadministration behavior in rhesus monkeys when compared to other PAL analogs, but the precise role of DA and 5-HT in mediating differences in behavioral responsiveness to these drugs remains unclear.
Few published studies have reported the effects of PAL compounds on extracellular DA and 5-HT in reward-relevant brain regions, and no experiments have assessed neurochemical and behavioral effects of these analogs in the same experimental subjects. To this end, we used in vivo microdialysis to examine the effects of PAL compounds on extracellular DA and 5-HT in the n. accumbens of rats that were housed in chambers equipped with photobeams to This article has not been copyedited and formatted. The final version may differ from this version. Intracerebral guide cannulae made of plastic (CMA 12, CMA/Microdialysis, Acton, MA) were implanted above the n. accumbens (N=7 rats/drug), according to stereotaxic coordinates: 1.6 mm lateral and 1.6 mm anterior to bregma, and 6.0 mm below the surface of dura (Paxinos, 1982) . Guide cannulae were secured to the skull using stainless steel anchor screws and dental acrylic. Animals were individually housed post-operatively and allowed 7-10 days for recovery.
Drugs and reagents.
The synthesis of PAL-series compounds was described by Wee et al (Wee et al., 2005) . All drugs were dissolved in saline immediately before use and administered i.v. in a volume of 1 ml/kg. Doses are expressed as the HCl salt. Sources of reagents required for microdialysis and HPLC methods have been previously reported (Baumann et al., 2008; Zolkowska et al., 2009 ).
Microdialysis methods.
In vivo microdialysis sampling was carried out as described, with minor modifications (Zolkowska et al., 2009 ). On the evening before an experiment, rats were moved to the testing room and briefly anesthetized with the short-acting barbiturate, exported to a Millennium software system (Waters Associates, Milford, MA, USA) for peak amplification, integration, and analysis. A monoamine standard mix containing DA, 5-HT and their respective acid metabolites was injected before and after the experiment to insure validity of constituent retention times. Peak heights of unknowns were compared to peak heights of standards, and the lower limit of assay sensitivity (3 x baseline noise) was 50 fg/ 5 µL sample.
Locomotor Measures. Locomotor measures were obtained as described, with minor modifications (Baumann et al., 2008) . During the overnight acclimation period and while undergoing microdialysis, each rat was housed within a square Plexiglass arena (43 cm length x 43 cm width x 43 cm height) that was equipped with an activity monitoring system (Tru Scan, Coulbourn Instruments). A sensor ring lined with photobeams spaced 2.54 cm apart was positioned in the horizontal plane to allow for real-time monitoring of various motor parameters.
Activity was monitored in 20-min bins, beginning 60 min before i.v. drug injections and continuing for 120 min thereafter. Ambulation and stereotypy were quantified separately; ambulation is defined as the total distance traveled in the horizontal plane (measured in cm), whereas stereotypy is defined as the number of photobeam breaks less than ± 1.5 beam spaces and back to the original point, that do not exceed 2 sec apart (measured in number of events).
Data analyses.
Group data are expressed as mean ± SEM for N=7 rats/group.
Neurotransmitter and behavioral data from individual rats were normalized to percent control values (i.e., % basal) using the averaged raw data from three preinjection time points as basal, or 100%. In this manner, each rat served as its own control. Normalized group data were evaluated by a two-factor analysis of variance (ANOVA) (Drug, Time). Subsequently, the individual time-effect curve for each drug was assessed by one-factor ANOVA; if this analysis demonstrated a significant main effect, data from time points after 1 mg/kg (20, 40 and 60 min) This article has not been copyedited and formatted. The final version may differ from this version. The effects of PAL compounds on stereotypy (i.e., repetitive movements) are shown in Table 1 ). All of the PAL drugs produced elevations in extracellular concentrations of DA and 5-HT in the n.
accumbens, but effects on dialysate DA did not agree with in vitro DA release data. Specifically, drug-induced increases in extracellular DA varied inversely with increases in 5-HT, suggesting that 5-HT is capable of reducing DA release and its associated hyperactivity. In agreement with our previous work, dialysate DA responses in the n. accumbens were positively correlated with stereotypy and ambulation, whereas 5-HT was correlated only with stereotypy (Baumann et al., 2008; Zolkowska et al., 2009) . Importantly, the ratio of DA/5-HT responses across all drug treatments was positively correlated with ambulation, suggesting an inhibitory role for 5-HT in modulating motor activity.
Our microdialysis study is the first to assess the effects of PAL analogs on extracellular DA and 5-HT in rat n. accumbens. All drugs evoked dose-related increases in dialysate DA, and the rank order of DA response magnitude at 3 mg/kg was PAL-353 = PAL-303 > PAL314 > PAL-313. This relationship does not agree with in vitro results showing the drugs have similar DA-releasing ability (see Table 1 ). The microdialysis data are consistent with the report of proposal, and future studies should address this hypothesis (Di Giovanni et al., 2008; Di Matteo et al., 2008) .
Based on the present data alone it is impossible to discount alternative mechanisms, We observed that all PAL analogs increased ambulation and stereotypy, but the extent of ambulation varied with drug treatment. Importantly, the level of stereotypy was similar across treatment groups, indicating that differences in ambulation cannot be explained on the basis of physiological antagonism whereby enhanced stereotypy reduces ambulation. The rank order of ambulatory response magnitude at 3 mg/kg was PAL-353 > PAL-303 > PAL314 = PAL-313.
This relationship parallels n. accumbens DA elevations shown in Fig. 2 and confirms prior results that relied on behavioral scoring methods to reveal differences in locomotor sensitivity to PAL drugs (Rothman and Baumann, 2006) . It is well established that DA nerve terminals in the n. accumbens are critical substrates of the behavioral-activating effects of amphetamine-type whereas PAL-313, PAL-287 and the 5-HT releaser fenfluramine do not (Kimmel et al., 2009 ). In rhesus monkeys, the rank order of potency to produce cocaine-appropriate responding in a drug discrimination assay is PAL-353 > PAL-314 > PAL-287 > fenfluramine (Negus et al., 2007) . As noted previously, PAL-313 engenders significantly less self-administration behavior when compared to other PAL analogs tested in the present study (Wee et al., 2005) . Collectively, such findings indicate that 5-HT release attenuates stimulant properties of amphetamine-type drugs in a consistent manner across a variety of behavioral assays in diverse species.
Clinical trials conducted over the last decade reveal that monoamine releasers are promising treatment adjuncts for cocaine addiction (Mooney et al., 2009; Herin et al., 2010) .
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